Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822393 | 0.89 | KDM4E (0.42) | KDM4EKMT2AGFERRXFP1MAPT | |
| SCHEMBL10792029 | 0.88 | KDM4E (0.48) | KDM4EMAPTALDH1A1HSD17B10LMNA | |
| SCHEMBL7349741 | 0.83 | KDM4E (0.60) | KDM4EHTR4MAPTPOLBALDH1A1 | |
| SCHEMBL28431565 | 0.80 | XDH (0.40) | KDM4EKMT2AGFERRXFP1MAPT | |
| SCHEMBL4882971 | 0.80 | KDM4E (0.41) | KDM4EKMT2AGFERRXFP1MAPT | |
| SCHEMBL11662563 | 0.79 | KDM4E (0.48) | KDM4EKMT2AGFERRXFP1MAPT | |
| SCHEMBL14995541 | 0.79 | BAZ2B (0.43) | KDM4EHTR4MAPTALDH1A1HSD17B10 | |
| SCHEMBL7402316 | 0.79 | ALDH1A1 (0.55) | KDM4EKMT2AHTR4MAPTMEN1 | |
| SCHEMBL22227681 | 0.78 | SELL (0.47) | KDM4EKMT2AMAPTTDP1MEN1 | |
| SCHEMBL130553 | 0.78 | MAPT (0.37) | KDM4EKMT2AHTR4MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-6248757-B1 | ANTISEROTONINE AGENTS | SANOFI-SYNTHELABO (FR) | 2001-06-19 | — | — | US | disclosed |
| US-5929089-A | ANTISEROTONINE AGENT | SYNTHELABO (FR) | 1999-07-27 | — | — | US | disclosed |
| EP-0863897-B1 | 5-PHENYL-3-(PIPERIDIN-4-YL)-1,3,4-OXADIAZOL-2(3H)-ONE DERIVATIVES FOR USE AS 5-HT4- OR H3-RECEPTOR LIGANDS | SYNTHELABO (FR) | 1999-06-16 | — | — | EP | disclosed |
| CN-1040436-C | Pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
| US-4323503-A | PSYCHOFUNCTION PROPERTIES SUCH AS ANXIOLYTIC OR PSYCHOSTIMULANT | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1982-04-06 | — | — | US | disclosed |
| US-4306072-A | ANXIOLYTIC AND PSYCHOSTIMULANT ACTIVITY FOR TREATMENT OF PSYCHOLOGICAL DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE (FR) | 1981-12-15 | — | — | US | disclosed |
| US-4268512-A | ANXIOLYTIC AGENTS, PSYCHOSTIMULANTS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-05-19 | — | — | US | disclosed |
| US-4255580-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | SIOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-03-10 | — | — | US | disclosed |
| US-4248885-A | FOR GASTROINTESTINAL, UROGENITAL, RHEUMATIC, AND CARDIOVASCULAR DISEASE | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-02-03 | — | — | US | disclosed |
| US-4186135-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | KDM4E 1073/4885KMT2A 1193/4885GFER 950/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | KDM4E 323/4885KMT2A 349/4885GFER 1519/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | KDM4E 650/4885KMT2A 720/4885GFER 2668/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | KDM4E 1073/4885KMT2A 1193/4885GFER 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.